Fu-Kuen Lin, a research scientist at Amgen, was the first to
clone a gene for a complex biologic, erythropoietin, in 1983. Amgen and Lin
received the 1995 Discoverers Award from Pharmaceutical Research and
Manufacturers of America for the development of the first man-made injectable
version of erythropoietin.5,6
Since the development of recombinant erythropoietin, Amgen has
continued to develop innovative biologic medicines that have changed the way we
treat cancer, rheumatoid arthritis, osteoporosis, and other serious illnesses.
Other biologic medicines include vaccines, blood components, insulin, and monoclonal antibodies (mAbs), all of
which have been instrumental in treating millions of patients worldwide.